Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carotuximab (TRC105) Clear all
Terminated Phase 2 Interventional Results available

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

NCT02664961
View directory record Official record
Conditions
Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
Interventions
TRC105, Bevacizumab
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
16 Years to 99 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

NCT01727089
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

NCT01564914
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
TRC105, Bevacizumab
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 30, 2026, 10:40 PM EDT
Recruiting Phase 1 Interventional

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

NCT05401110
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
Osimertinib, Carotuximab
Drug
Lead sponsor
Karen Reckamp, MD, MS
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Beverly Hills, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

NCT02520063
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Everolimus, TRC105
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

NCT01328574
View directory record Official record
Conditions
Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral, Cancer of the Ureter
Interventions
TRC105
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

NCT02979899
View directory record Official record
Conditions
Advanced Angiosarcoma
Interventions
TRC105, Votrient
Biological · Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
26
States / cities
Tucson, Arizona • Palo Alto, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 30, 2026, 10:40 PM EDT
No Longer Available No phase listed Expanded access

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

NCT02354612
View directory record Official record
Conditions
Solid Tumors
Interventions
TRC105, Bevacizumab, Axitinib, Pazopanib, Capecitabine
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

NCT01381861
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Interventions
Carotuximab (TRC105)
Biological
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1 Interventional

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

NCT02429843
View directory record Official record
Conditions
Lung Cancer
Interventions
TRC105
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

NCT03418324
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRC105, Abiraterone, Enzalutamide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

NCT01326481
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
TRC105, Capecitabine
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

NCT01090765
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer
Interventions
TRC105
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1 Interventional Results available

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

NCT01332721
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
TRC105 and Bevacizumab
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1 Interventional Results available

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

NCT03181308
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Carotuximab (TRC105), OPDIVO
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 30, 2026, 10:40 PM EDT
Terminated Phase 2 Interventional Results available

TRC105 for Recurrent Glioblastoma

NCT01778530
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TRC105
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib and TRC105 in Hepatocellular Cancer

NCT01306058
View directory record Official record
Conditions
Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, Carcinoma, Hepatocellular, Liver Neoplasms, Experimental
Interventions
TRC 105, Sorafenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

NCT02396511
View directory record Official record
Conditions
Choriocarcinoma
Interventions
TRC105, Bevacizumab
Biological
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of TRC105 and Sorafenib in Patients With HCC

NCT02560779
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Carotuximab (TRC105), Sorafenib
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01648348
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
Interventions
Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
308
States / cities
Little Rock, Arkansas • Fullerton, California • Orange, California + 219 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

NCT01975519
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma
Interventions
TRC105 and Pazopanib
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 120 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 30, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

NCT01375569
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Carcinoma, Hepatocellular
Interventions
TRC105
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Sep 30, 2026, 10:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

NCT01806064
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
TRC105 and Axitinib, Axitinib
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 30, 2026, 10:40 PM EDT